NetEase Finance September 29th News In recent years，With ultra -low price，Indian generic drugs are popular globally，and in China also triggered a purchasing boom。This is for the Chinese pharmaceutical industry, which is about to be the second largest pharmaceutical market in the world，The embarrassment or the difficult place is unspeakable。
    Now，With a large number of foreign patented drugs expired、Domestic related policies tend to loosen，China's generic drug industry is ushered in an unprecedented & ldquo;，By 2015, the market size may be close to 500 billion yuan。But this does not mean that domestic pharmaceutical companies can comfortably take good lives，Technical ability backward，Factors such as industrial development are still huge gaps。
    After two years, the domestic generic drug market may reach 500 billion
    Recently，A couple in Nanshan District, Shenzhen，After buying anticancer drugs in India，Selling in China through Taobao。Because the medicine does not have legal channels，It is characterized by the drug supervision department as a fake medicine，The two were also detained by the police for suspected sale of fake drugs。but but，With the couple being sentenced to punishment for purchasing anti -cancer drugs for purchasing anti -cancer drugs，Indian generic drugs have also attracted more and more attention in China。
    for a long time，With its low cost and price，India is independent in the field of generic drugs，Even the name of the world pharmacy & rdquo;，Its generic drug industry is very developed。Generally speaking，Once expensive medicines in Western countries are listed，Indian pharmaceutical companies can imitate similar products under the protection of their national patent law。
    Indian pharmaceutical Stake Sports BettingMy stake betting appcompanies' & ldquo under the country's protection is & rdquo; often makes Chinese pharmaceutical companies envious，Now，This sour feeling seems expected to be dispersed by the market's great changes。
    The reason why you say that，First is the data display，From January 1, 2012 to 5 years from December 31, 2016，There will be as many as 631 patented medicines in the world。This is for many developing countries，It means that there will be more market space in generic drugs。
    In addition，The potential for development of the Chinese pharmaceutical market is huge。Analysis report display，By 2015, China will become the world's second largest pharmaceutical market country (including compound Chinese medicine)。China is the fastest growing pharmaceutical market in the world，between 2012 and 2017，The average annual growth rate of the Chinese pharmaceutical market will reach 16.7%。
    & ldquo; Patented cliffs (drug patents are about to expire) to create huge opportunities for generic pharmaceutical companies，Original drugs generally need to develop in about 10-15 years、Approval and mass production，R & D expenses for heavy varieties may be as high as billions of dollars。Compared with，The process of generic drugs is greatly simplified and the cost is reduced a lot，It is expected to be around 2015，Domestic generic drug scale may be close to 500 billion yuan & rdquo;，A researcher at China Merchants Securities pointed out。
    Industry insiders pointed out，Current，The world's drug market has only 4%to 5%of low -speed growth annual，But the industrial industry of generic drugs and biotechnology has stood out，The annual analogy of 11%and 10%is becoming a vitality section leading the sustainable development of the global industry，At the same time, it also inspired a emerging market & mdash; & mdash; biological generic drug industry。
    Domestic pharmaceutical companies have seized the varieties of high -gross -profit generic drugs
    Faced with foreign pharmaceutical companies & ldquo; patent cliff & rdquo;，Chinese generic drugs have long grinded Hoho and waited for the market to open the market。Guo Fanli, Manager of the Research Department of China Investment Consultant Industry，The strength of Chinese pharmaceutical companies in the development of generic drugs is getting stronger and stronger，The efficacy of the drug is not weaker than patented medicine，Being able to divide into a generic drug market。In the future, the threshold of China's generic drug industry will be further improved，High -quality new varieties accelerate volume，High -quality generic drug market share increases，The concentration of competition gradually increases。
    stake sports betting appCurrent，my country can Stake Sports Bettingalready produce some biotechnology drugs，In 13 categories of 13 categories of 382 different specifications of genetic engineering drugs and genetic engineering vaccine products,，There are 6 categories of 9 only 21 specifications of products belong to the original，The rest belongs to imitation。
    Among more than 100 biopharmaceutical varieties in China，Most of them belong to improved imitation。Haizheng Pharmaceutical、Consistent Pharmaceutical、Fosun Medicine、Shuanglu Pharmaceutical、Lizhu Group、Anke Bio、Tonghua Dongbao and other companies are also actively deploying and developing monoclonal antibodies or long -acting reorganized protein drugs。
    Data display，The proportion of the output value of biopharmaceuticals in my country has risen from 7.91%in 2006 to 16.1%in 2011，Proportion of profit rose from 10.3%in 2006 to 13.7%。From the perspective of the drug type，Analysis of market prospects，monoclonal anti -anti -anti -drug shows good results and market acceptance in the treatment of cancer and rheumatoid diseases。
    It is worth noting is，In addition to pharmaceutical companies，More and more investment institutions have also discovered the opportunity of biotechnology drugs。A few days ago, the official opening of the Hebei Gu'an Peptide Valley Life Science Park, which was invested and operated by Huaxia Happiness Basic Co., Ltd.。This garden is trying to cooperate with enterprises and institutions on the biomedical industry chain，Integrated elements of innovation of the biomedical industry，Establish an incubation acceleration system，Promoting the development of biological generic drugs in my country。
    Xiao Ruiping, Director of the Peking University Institute of Molecular Medicine, who has entered the Peptide Valley Life Sciences Park, pointed out，At present, American biopharmaceuticals have accounted for 63%of the world's share，EU account for 25%，But with the rise of the Chinese biopharmaceutical industry，This pattern may soon change。
    In the specific imitation direction，& ldquo; Imitation drug investment depends on the strength and product line direction of the company，The ideas of each enterprise are different & rdquo;，Guo Fanli said。It is understood，In tumor、Hepatitis B、Diabetes、Asthma and other fields，The competition of generic drugs is even more intense，These areas represent the high gross profit of the generic drug market and the development direction of high expectations，At present, a considerable part of the domestic pharmaceutical companies are layout。
    Regulatory standards are too low and technical congenital weakness
    stake sports betting appbut，The seductive market stake betting appprospect cannot be converted into a real profit statement。Chinese pharmaceutical companies want to catch up with the spring of generic drugs，It also needs to prepare in many aspects such as external environment and internal strength。At least from the current point of view，Chinese pharmaceutical companies still & ldquo; cannot stop porcelain living & rdquo;。
    & ldquo; Compared with India, the biggest difference between imitations in my country is the policy & rdquo;，Guo Fanli, Manager of the Research Department of China Investment Consultant Industry。Public information display，Indian tradition has rarely provided patent protection for companies that have long -term investment in drug research and development，Indian pharmaceutical companies are also more focused on the development of generic drugs，Once there are new drugs entering the market，They quickly launch similar medicines。and in China，It is a clear protection for patents，Encourage the development of new drugs，This also makes pharmaceutical companies enthusiasm for developing new drugs under the protection of policy protection。
    Except the patent system needs to be broken，China Drug Quality Supervision and other series of indicators also need to be improved。Industry experts point out，The quality standard of the generic drug performed by China is too low，The technical threshold for technical review requirements is too low，So that domestic pharmaceutical companies can reach the standard without in -depth research。So，Some generic drugs in China are currently only chemical equivalent，and the creature is equivalent to、Safety equivalent、Clinical equivalent is still out of reach。
    & ldquo; There is no problem in the active component of domestic approved and listed generic drugs，But the active ingredient is just a part of the few medicines，More auxiliary materials。Gap at home and abroad，In fact, it is often reflected in the quality of the auxiliary materials & rdquo;，Professor Qiu Lizhen, a professor at the School of Pharmacy of Zhejiang University, expressed to NetEase Finance。
    but，Even if there are many foreign patents expiration and national policy and policy relaxation，Not every Chinese -funded pharmaceutical company can make a share。& ldquo; Patented cliffs are not imitations waiting for pharmaceutical companies，Pharmaceutical companies that are not outstanding in research and development capabilities are actually difficult to intervene in the field of generic drugs。& rdquo; Some analysts point out。
    Imitation drugs are not casual cottage goods，On the international market，All countries have strict requirements on generic stake sports betting appdrugs。But in the actual stake betting appexecution process，Domestic pharmaceutical companies have a serious tendency for roughness and abuse，Objectively turning generic drugs into cottage medicine，But in fact there is a essential difference between the two。
    Industry insiders pointed out，The quality of some generic drugs that have been listed in my country cannot be said on the same day as the original research drugs，The manifestation in clinical practice is even more unsatisfactory，A considerable part of & ldquo; safety、Infernal & rdquo; and & ldquo; safety、Not very effective & rdquo;。
    On the current Chinese market，The status quo of domestic drugs is almost the status quo of generic drugs，About 95%of domestic medicines are generic drugs。China is the actual imitic drug country，But far from the power of imitation drugs。The common self -determination of the Chinese pharmaceutical industry is: & ldquo; There is a large gap between the quality of some generic drugs in my country and the international advanced level。(Author Zhao Ting，Yang Xiaoyan also contributed to this article)

    Source: NetEase Finance